Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest - discu.eu

Reddit

$DVAX- Dynavax with a short interest of 20% and their partner Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest https://www.prnewswire.com/news-releases/clovers-covid-19-vaccine-candidate-demonstrates-79-efficacy-against-delta-in-global-phase-23-spectra-trial-dominated-by-variants-of-concern-and-interest-301382628.html 10 comments 22/9/2021 wallstreetbets

Linked pages

CEPI | New Vaccines For A Safer World https://cepi.net/ 0 comments

Related searches:

Search whole site: site:www.prnewswire.com

Search title: Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest

See how to search.

Submit link to: